Member Info for Theanalyzer

A demo version only 15 months after RTO - impressive stuff.

1 why no RNS?
2 How did pay it doesn’t have any cash?

T212 SYME is listed on standard not premium segment of LSE perhaps that is the issue? However, it was a standard list even before RTO so sounds a little odd.

Peakhope. You should not place too much weight on fact that Negma was prepared to offer £50 million cash via issuance of £56 million in loan notes. This isn’t standard debt finance. EGHOS a similar lender was prepared to offer Iconic a similar sum as an essentially insolvent shell.

Could TF vendors take SYME shares worth £4 million in placing and pay for it by returning the £4 million they got paid fly SYME in cash for TF shares?

This would enable SYME to repay Negma.

Only going to happen if TF vendors feel super confident about SYME business and TF get larger stake in business?

Nbul1. Looks like to claims to be buying have been called out by Mr Amir. Back to ramper school for you.

Guitarman. The remaking million of convertible will have to be either repaid in cash or by conversion into shares.

Even if Tradeflow shareholders now agree to take £4 million in cash in shares SYME need to repay the £4 million.

An issue of £ 4 million of shares should be easy for a company with SYME’s market cap.

Perhaps failure of this merger of broking giants may result in some new talent looking for backers.

The platform sector is both consolidating rapidly and also now attracting big buyers.

M&G bought Royal London’s platform previously, it lacked scale and was loss making.

Happy to hold such a fast growing business.

Looks like LSE is now duplicating all trades for some reason?

nbul1 still waiting for some of your insightful researches to why you bought this share.

BrassGeminin Whenever a novel accounting treatment for a product is designed it remains the responsibility of management and their auditors of the user of the accounting product to ensure that they concur with the proposed treatment. The vendor of the solution will provide the basis for their arguments but it remains obligation of buyer to accept the treatment.

The major investment banks amongst other often generate such schemes for regulatory and tax arbitrage purposes. Upfront support for such products by a Big 4 accounting technical treatment is a common practice to try and make it easier for the buyer to sort out accounting hurdles.

Extrader
IAS 39 was superseded by IFRS 9 on 1 Jan 2018 so it looks like you need to buy a new accounting manual. In any case you are looking at wrong standard in any case because what matters is whether customers can record a sale under IFRS 15 Revenue when entering into the trade. There are some hurdles to be overcome in IFRS 15 such as bill and hold clauses, the nature of any repurchase rights and obligations etc but AZ claims he sorted these issues out with 2 of the Big 4.

Nbul1. RNS this am Directors being paid partly in shares to conserve cash. No doubt this is a buy signal for you.

Doctor Shipman
No funding for IM is what I meant and you know it

SYME positives

Great concept with huge market potential
Tradeflow acquisition
No immediate liquidity issues

SYME negatives

CEO over promises and under delivers
No funding for concept 15 months after IPO
No financials yet provided for Tradeflow eg revenue, profit or funds under management
No replacement Chairman - for potential Fintech giant before existing Chair left
Negma death spiral
Loss making
Market cap primarily supported by hope
Low calibre NED just appointed
Unable to attract institutional Fintech investors

Miler a Vice President at Deutche Bank sounds impressive but there are literally hundreds of such Vice Presidents.

It is meant to sound impressive but if you work their 5 plus years you can’t the title.

Vive Bank is now inactive. Got its Bank of England licence then shut down.

So as CFO Bull only had to mange expenses and forecasts in start up phase - not exactly leading edge stuff.

Joeman1. Ian Grey one of the Directors is former CEO of innovate U.K. so no that far away from MattHanc0ck type deals

Nbul1. If you want share to go up, why not share some of your research insights which might persuade others holders to top up and cynics like me to stop posting. The floor is yours…